🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Renmin Hospital of Wuhan University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Renmin Hospital of Wuhan University as lead sponsor. Synced 26 Sep 2026
21Current trials
13Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Renmin Hospital of Wuhan University is the lead sponsor of 21 current clinical trials in our China register. 13 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Cyclophosphamide, Prednisone and Telitacicept. The most-studied condition is Artificial Intelligence.

ClinicalTrials.gov trials by status

  • Recruiting1362%
  • Not yet open629%
  • Active, closed210%

Trials by phase

  • Not applicable943%
  • Observational838%
  • Phase 2210%
  • Phase 1/215%
  • Phase 315%
01

Clinical trials sponsored by Renmin Hospital of Wuhan University

21 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
NCT03972956 · ClinicalTrials.gov ↗ · Colorectal Cancer, Gastric Cancer, Inflammatory Bowel Diseases
Observational Recruiting 2020-12 China
Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
NCT05894369 · ClinicalTrials.gov ↗ · Esophageal Cancer
Observational Recruiting 2023-05 China
Artificial Intelligence-assisted System in Colonoscopy
NCT06406062 · ClinicalTrials.gov ↗ · Adenoma Colon Polyp
Observational Recruiting 2024-05 China
Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases
NCT07595068 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF), Cardiovascular Diseases
Not applicable Recruiting 2026-05 China
Application Evaluation Research on the Artificial Intelligence-assisted Support System for the Diagnosis of Colorectal Tubular Adenoma Lesions
NCT07073430 · ClinicalTrials.gov ↗ · Colorectal Adenoma, Artificial Intelligence (AI)
Observational Recruiting 2023-11 China
Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions
NCT06039917 · ClinicalTrials.gov ↗ · Artificial Intelligence, Surveillance
Not applicable Recruiting 2023-09 China
Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma
NCT05563012 · ClinicalTrials.gov ↗ · Disorder in Complete Remission in Response to Treatment
Phase 2 Recruiting 2022-09 China
Multicenter Study on Postoperative Urinary and Sexual Function During Laparoscopic Functional Total Mesorectum Excision
NCT05049317 · ClinicalTrials.gov ↗ · Rectal Cancer
Not applicable Recruiting 2021-11 China
Wuhan High Myopia Study
NCT06162234 · ClinicalTrials.gov ↗ · High Myopia
Observational Recruiting 2023-12 China
Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction
NCT07587294 · ClinicalTrials.gov ↗ · Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)
Not applicable Recruiting 2026-05 China
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
NCT05919030 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma
Phase 3 Recruiting 2023-07 China
Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock
NCT07085221 · ClinicalTrials.gov ↗ · Shock, Cardiogenic, Shock
Not applicable Recruiting 2025-07 China
Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.
NCT06429969 · ClinicalTrials.gov ↗ · Vitreoretinal Disease
Observational Recruiting 2024-01 China
Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhinitis: A Multicenter, Randomized, Double-blind, Controlled Trial
NCT07269509 · ClinicalTrials.gov ↗ · Allergic Rhinitis
Not applicable Not yet open 2025-12 China
Early Diagnosis Model of Colorectal Adenoma Using Laboratory Examinations
NCT07793110 · ClinicalTrials.gov ↗ · Colorectal Adenoma, Polyp
Observational Not yet open 2026-09 China
Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients
NCT05894850 · ClinicalTrials.gov ↗ · Artificial Intelligence, Surveillance
Not applicable Not yet open 2023-06 China
Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients
NCT05751824 · ClinicalTrials.gov ↗ · Artificial Intelligence, Surveillance
Not applicable Not yet open 2023-02 China
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
NCT06614985 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy
Phase 2 Not yet open 2024-10 China
Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer
NCT03127111 · ClinicalTrials.gov ↗ · Stage III Colorectal Cancer
Observational Not yet open 2022-12 China
The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)
NCT06656962 · ClinicalTrials.gov ↗ · Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)
Phase 1/2 Active, closed 2024-10 China
A Prospective Study of Cold Exposure in Patients With MASH
NCT07821749 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Not applicable Active, closed 2026-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Renmin Hospital of Wuhan University trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Renmin Hospital of Wuhan University trials

26 conditions
Artificial Intelligence3Surveillance3Colorectal Adenoma2Colorectal Cancer1Gastric Cancer1Inflammatory Bowel Diseases1Gastric Ulcer1Esophageal Cancer1Adenoma Colon Polyp1Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)1Atrial Fibrillation (AF)1Cardiovascular Diseases1Artificial Intelligence (AI)1Metabolic Dysfunction-Associated Steatohepatitis (MASH)1Allergic Rhinitis1Disorder in Complete Remission in Response to Treatment1Polyp1Rectal Cancer1High Myopia1Primary Membranous Nephropathy1Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)1Esophageal Squamous Cell Carcinoma1Stage III Colorectal Cancer1Shock, Cardiogenic1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2113

A trial with sites in more than one country appears in each of those registers.

05

Questions about Renmin Hospital of Wuhan University trials

How many clinical trials does Renmin Hospital of Wuhan University sponsor?

Renmin Hospital of Wuhan University is the lead sponsor of 21 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Renmin Hospital of Wuhan University trials recruiting?

Yes. 13 of its 21 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Renmin Hospital of Wuhan University testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Cyclophosphamide (2), Prednisone (2), Telitacicept (2), Cisplatin (1) and Methylprednisolone (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.